AtriCure, Inc. - Common Stock (ATRC)
Frequently Asked Questions About AtriCure, Inc. - Common Stock (ATRC)
Has AtriCure received any awards or recognition?
AtriCure has received various awards and recognitions for its innovative medical devices and contributions to the field of cardiac surgery. These accolades reflect the company’s commitment to excellence and impact on improving patient care.
How does AtriCure contribute to research and development?
AtriCure places a strong emphasis on research and development to continuously innovate and improve its product offerings. The company invests in clinical studies and collaborates with leading healthcare professionals to advance knowledge and improve treatment protocols in cardiac surgery.
How does AtriCure support healthcare professionals?
AtriCure provides comprehensive support to healthcare professionals through education and training programs on the use of their devices. This includes resources for best practices, clinical guidance, and ongoing technical support to ensure safe and effective procedures.
Is AtriCure a publicly traded company?
Yes, AtriCure, Inc. is a publicly traded company. It became publicly listed on the Nasdaq in 2005, allowing it to raise capital for its operations and growth through the sale of stock to investors.
What are AtriCure's growth strategies?
AtriCure's growth strategies focus on expanding its product portfolio, entering new markets, and enhancing its sales and marketing efforts. The company aims to leverage partnerships and collaborations to accelerate innovation and adoption of its technologies worldwide.
What are the benefits of AtriCure's technologies?
AtriCure's technologies offer several benefits, including improved patient outcomes, reduced recovery times, and minimally invasive procedures. The company's devices are designed to enhance surgical accuracy, providing surgeons with tools that enable effective treatment options for patients with complex arrhythmias.
What are the future prospects for AtriCure?
The future prospects for AtriCure appear promising, with increasing demand for innovative cardiac therapies driven by the rising prevalence of atrial fibrillation. The company aims to capitalize on market growth opportunities, enhance its product line, and continue advancing in the field of cardiac surgery.
What clinical evidence supports AtriCure's products?
AtriCure's products are supported by extensive clinical evidence demonstrating their safety and efficacy in treating atrial fibrillation and related conditions. The company participates in clinical trials and gathers real-world data to validate its technologies and enhance their utilization.
What does AtriCure, Inc. do?
AtriCure, Inc. is a medical device company dedicated to developing innovative technologies for the treatment of atrial fibrillation (Afib) and other cardiac arrhythmias. Their product portfolio includes devices that enable surgeons to perform procedures aimed at isolating or eliminating areas of the heart responsible for abnormal electrical signals.
What is atrial fibrillation?
Atrial fibrillation (Afib) is a common type of heart rhythm disorder characterized by irregular and often rapid heartbeat. It can lead to an increased risk of stroke, heart failure, and other heart-related complications, making effective treatment essential for patients.
What is AtriCure's mission statement?
AtriCure's mission is to create technologies that advance the standard of care in the treatment of atrial fibrillation and other cardiac arrhythmias. The company aims to improve patients' lives through innovation, collaboration, and exceptional service to healthcare providers.
What is AtriCure's stock symbol?
AtriCure's stock symbol is ATRC, and its shares are traded on the Nasdaq Stock Market. This symbol is used to identify the company in stock trading and financial markets.
What is the role of AtriCure's management team?
AtriCure's management team is responsible for overseeing the company's strategic direction, financial performance, and operational execution. The team consists of experienced professionals from the medical device and healthcare industries who drive the company’s mission and growth.
What is the significance of minimally invasive surgical techniques?
Minimally invasive surgical techniques, such as those promoted by AtriCure, offer significant advantages over traditional surgery, including reduced scarring, shorter recovery times, and lower risk of complications. These techniques improve overall patient experience and outcomes.
What markets does AtriCure serve?
AtriCure primarily serves the cardiac surgery market, focusing on hospitals and surgical centers involved in treating patients with atrial fibrillation and other arrhythmias. Their products are used globally, with significant markets in North America, Europe, and Asia.
What products does AtriCure offer?
AtriCure offers a range of products designed for cardiac surgical procedures. Their key offerings include radiofrequency ablation devices, cryoablation systems, and various accessories that assist in treating atrial fibrillation and enhancing surgical outcomes.
When was AtriCure founded?
AtriCure, Inc. was founded in 2000. Since its inception, the company has focused on creating advanced solutions to improve the surgical treatment of cardiac arrhythmias, particularly through its innovative ablation technologies.
Where is AtriCure headquartered?
AtriCure is headquartered in Mason, Ohio, USA. This location is part of the Greater Cincinnati area, where the company has established its primary facilities for research, development, and corporate operations.
Who are AtriCure's main competitors?
AtriCure competes with other medical device companies focusing on cardiac care, such as Abbott Laboratories, Medtronic, and Boston Scientific. These competitors also develop products aimed at addressing atrial fibrillation and other heart conditions.
What is the current price of AtriCure, Inc. - Common Stock?
The current price of AtriCure, Inc. - Common Stock is 33.67
When was AtriCure, Inc. - Common Stock last traded?
The last trade of AtriCure, Inc. - Common Stock was at 4:00 pm EDT on April 28th, 2025
What is the market capitalization of AtriCure, Inc. - Common Stock?
The market capitalization of AtriCure, Inc. - Common Stock is 1.54B
How many shares of AtriCure, Inc. - Common Stock are outstanding?
AtriCure, Inc. - Common Stock has 45.88M shares outstanding.